TITLE:
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

CONDITION:
Melanoma

INTERVENTION:
MDX-010 (CTLA-4)

SUMMARY:

      The objectives of this study are to determine the safety and activity profile of multiple
      doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy
      (decarbazine [DTIC]) can augment the effects of MDX-010 in patients with chemotherapy nave
      metastatic melanoma with a tolerable toxicity profile.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Clinical diagnosis of unresectable metastatic melanoma.

          -  No prior chemotherapy for melanoma, and no chemotherapy for other malignancies within
             5 years and at least 4 weeks since treatment (surgery, radiation, or immunotherapy)
             for melanoma.

        Exclusion Criteria

        Patients who exhibit any of the following conditions at screening will not be eligible for
        admission into the study:

          -  Any other prior malignancy, except for the following: adequately treated basal or
             squamous cell skin cancer or superficial bladder cancer, or any other cancer from
             which the patient has been disease-free for >=5 years.

          -  Active autoimmune disease.

          -  Active infection requiring therapy, or chronic active HBV or HCV, or confirmed
             reactivity with HIV tests.
      
